151 related articles for article (PubMed ID: 35675136)
1. Incremental Value of 18F-PSMA-1007 PET/CT in Detection of Metastatic Renal Cell Carcinoma to the Brain.
Sadeq A; Usmani S; Esmail AA; Fathallah W; Alfeeli MA; Marafi F
Clin Nucl Med; 2022 Jul; 47(7):627-628. PubMed ID: 35675136
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. Potential role of
Aggarwal P; Singh H; Das CK; Mavuduru RS; Kakkar N; Lal A; Gorsi U; Kumar R; Mittal BR
Eur J Radiol; 2024 Jan; 170():111218. PubMed ID: 38007857
[TBL] [Abstract][Full Text] [Related]
4. 18F-PSMA-1007 PET/CT for Initial Staging of Renal Cell Carcinoma in an End-Stage Renal Disease Patient.
Marafi F; Sasikumar A; Aldaas M; Esmail A
Clin Nucl Med; 2021 Jan; 46(1):e65-e67. PubMed ID: 33181733
[TBL] [Abstract][Full Text] [Related]
5. 68Ga-PSMA PET/CT Detecting Metastatic Lesion of RCC: Missed on 18F-FDG PET/CT.
Jha S; Hemrom A; Shamim SA; Barwad A; Batra A
Clin Nucl Med; 2023 Jun; 48(6):e294-e296. PubMed ID: 37133514
[TBL] [Abstract][Full Text] [Related]
6. Head-to-head comparisons of enhanced CT, 68Ga-PSMA-11 PET/CT and 18F-FDG PET/CT in identifying adverse pathology of clear-cell renal cell carcinoma: a prospective study.
Chen SH; Lin BH; Chen SM; Qiu QR; Ruan ZT; Chen ZJ; Wei Y; Zheng QS; Xue XY; Miao WB; Xu N
Int Braz J Urol; 2023; 49(6):716-731. PubMed ID: 37624658
[TBL] [Abstract][Full Text] [Related]
7.
Parghane RV; Basu S
J Nucl Med Technol; 2023 Sep; 51(3):261-262. PubMed ID: 36041875
[TBL] [Abstract][Full Text] [Related]
8. 18F-PSMA 1007 in Suspected Renal Cell Carcinoma.
Marafi F; Sasikumar A; Al-Terki A; Alfeeli M
Clin Nucl Med; 2020 May; 45(5):377-378. PubMed ID: 32209880
[TBL] [Abstract][Full Text] [Related]
9. 18F-PSMA-1007 Uptake in Paget Disease of the Bone: An "Iron Man" Sign.
Alfeeli M; Marafi F; Esmail A; Fathallah WMA; Usmani S
Clin Nucl Med; 2022 Mar; 47(3):249-250. PubMed ID: 34392292
[TBL] [Abstract][Full Text] [Related]
10. The role of dual tracer PSMA and FDG PET/CT in renal cell carcinoma (RCC) compared to conventional imaging: A multi-institutional case series with intra-individual comparison.
Tariq A; Kwok M; Pearce A; Rhee H; Kyle S; Marsh P; Raveenthiran S; Wong D; McBean R; Westera J; Dunglison N; Esler R; Navaratnam A; Yaxley JW; Thomas P; Pattison DA; Roberts MJ
Urol Oncol; 2022 Feb; 40(2):66.e1-66.e9. PubMed ID: 34895817
[TBL] [Abstract][Full Text] [Related]
11. Utility of
Siva S; Callahan J; Pryor D; Martin J; Lawrentschuk N; Hofman MS
J Med Imaging Radiat Oncol; 2017 Jun; 61(3):372-378. PubMed ID: 28116853
[TBL] [Abstract][Full Text] [Related]
12. Complementary Role of 68Ga-Prostate-Specific Membrane Antigen and 18F-FDG PET/CT for Evaluation of Metastases and Treatment Response in Renal Cell Carcinoma.
Has Simsek D; Civan C; Erdem S; Sanli Y
Clin Nucl Med; 2021 Jul; 46(7):579-581. PubMed ID: 33782292
[TBL] [Abstract][Full Text] [Related]
13. Inconsistent Detection of Sites of Metastatic Non-Clear Cell Renal Cell Carcinoma with PSMA-Targeted [
Yin Y; Campbell SP; Markowski MC; Pierorazio PM; Pomper MG; Allaf ME; Rowe SP; Gorin MA
Mol Imaging Biol; 2019 Jun; 21(3):567-573. PubMed ID: 30218388
[TBL] [Abstract][Full Text] [Related]
14. Comparison of 68Ga-PSMA-HBED-CC and 18F-FDG PET/CT in the Evaluation of Adenoid Cystic Carcinoma-A Prospective Study.
Shamim SA; Kumar N; Arora G; Kumar D; Pathak A; Thakkar A; Sikka K; Singh CA; Kakkar A; Bhalla AS
Clin Nucl Med; 2023 Nov; 48(11):e509-e515. PubMed ID: 37812520
[TBL] [Abstract][Full Text] [Related]
15.
Qi Z; Yao X; Su M; Huang R
Hell J Nucl Med; 2023; 26(2):155-156. PubMed ID: 37527052
[TBL] [Abstract][Full Text] [Related]
16. Clinical impact of Prostate-Specific Membrane Antigen Positron Emission Tomography (PET) on intensification or deintensification of advanced renal cell carcinoma management.
Pathmanathan S; Tariq A; Pearce A; Rhee H; Kyle S; Raveenthiran S; Wong D; McBean R; Marsh P; Goodman S; Dhiantravan N; Esler R; Dunglison N; Navaratnam A; Yaxley J; Thomas P; Pattison DA; Goh JC; Gan CL; Roberts MJ
Eur J Nucl Med Mol Imaging; 2023 Dec; 51(1):295-303. PubMed ID: 37592084
[TBL] [Abstract][Full Text] [Related]
17. Incidental Detection of Thyroid Metastases From Renal Cell Carcinoma Using 68Ga-PSMA PET/CT to Assess Prostate Cancer Recurrence.
Zacho HD; Nielsen JB; Dettmann K; Haberkorn U; Petersen LJ
Clin Nucl Med; 2017 Mar; 42(3):221-222. PubMed ID: 28033223
[TBL] [Abstract][Full Text] [Related]
18. 18F-FDG and 68GA-Prostate-Specific Membrane Antigen PET/CT Perform Better Than CT Alone in Restaging Papillary Renal Cell Carcinoma Recurrence.
Gasparro D; Scarlattei M; Manuguerra R; Guglielmo P; Migliari S; Sammartano A; Baldari G; Maestroni U; Silini EM; Ruffini L
Clin Nucl Med; 2021 Sep; 46(9):e458-e460. PubMed ID: 34374683
[TBL] [Abstract][Full Text] [Related]
19. Complimentary Pattern of Uptake in 18F-FDG PET/CT and 68Ga-Prostate-Specific Membrane Antigen PET/CT in a Case of Metastatic Clear Cell Renal Carcinoma.
Sasikumar A; Joy A; Nanabala R; Unni M; Tk P
Clin Nucl Med; 2016 Dec; 41(12):e517-e519. PubMed ID: 27749421
[TBL] [Abstract][Full Text] [Related]
20. A Multicenter Prospective Clinical Trial of
McCarthy M; Francis R; Tang C; Watts J; Campbell A
Int J Radiat Oncol Biol Phys; 2019 Jul; 104(4):801-808. PubMed ID: 30890448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]